Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CNTY 104

Drug Profile

CNTY 104

Alternative Names: CNTY-104

Latest Information Update: 24 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Century Therapeutics
  • Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Acute myeloid leukaemia

Most Recent Events

  • 10 Jan 2022 Century Therapeutics and Bristol Myers Squibb enters into a collaboration agreement to develop CNTY 104
  • 31 Aug 2021 Century Therapeutics announces intention to submit IND application to regulatory bodies for Acute myeloid leukaemia in the first half of 2024 (Century Therapeutics pipeline, August 2021)
  • 31 Aug 2021 Century Therapeutics pipeline, August 2021: NP created; intro, dev table, FET, planned trial HE and deal added, Thes drug term addition request sent; please update profile when more info available
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top